New triple therapy aims to shield kidneys in diabetes patients
NCT ID NCT07537088
First seen Apr 26, 2026 · Last updated May 11, 2026 · Updated 2 times
Summary
This study looks at whether adding a third medication (dulaglutide) to an existing two-drug regimen can provide extra kidney protection for Chinese adults with type 2 diabetes and mild-to-moderate chronic kidney disease. About 468 participants will either continue their current treatment or add dulaglutide for 26 weeks. The main goal is to measure changes in urine protein levels, a key marker of kidney health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2DM (TYPE 2 DIABETES MELLITUS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.